Med Check: Ulotaront Fails Phase 3, Cytisinicline vs Smoking Cessation, and FDA Warning
Ulotaront Fails Phase 3 Trials in Adults With Schizophrenia
Cytisinicline May Be Useful Intervention for Smoking Cessation
FDA, FTC Warn Companies for Illegally Selling Food Containing THC
Information & Authors
Information
Published In
History
Keywords
- ulotaront
- clinical trials
- psychosis
- schizophrenia
- sumitomo pharma
- otsuka pharmaceutical
- diamond 1 study
- diamond 2 study
- zuralonone
- postpartum depression
- skylark study
- american journal of psychiatry
- sage therapeutics
- biogen
- cytisinicline
- smoking cessation
- orca 2 trial
- jama
- achieve life sciences
- us food and drug administration
- fda
- federal trade commission
- ftc
- warning letter
- copycat food products
- delta 8 thc
- thc
- illegal thc
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).